Compare AORT & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AORT | OCS |
|---|---|---|
| Founded | 1984 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 3 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 1996 | N/A |
| Metric | AORT | OCS |
|---|---|---|
| Price | $38.57 | $28.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $49.40 | $42.00 |
| AVG Volume (30 Days) | ★ 415.0K | 189.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.62 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $298,836,000.00 | N/A |
| Revenue This Year | $14.20 | $466.06 |
| Revenue Next Year | $11.20 | $479.73 |
| P/E Ratio | $179.90 | ★ N/A |
| Revenue Growth | ★ 18.01 | N/A |
| 52 Week Low | $22.68 | $16.00 |
| 52 Week High | $48.25 | $30.68 |
| Indicator | AORT | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 58.61 | 64.37 |
| Support Level | $34.15 | $19.05 |
| Resistance Level | $44.29 | $29.19 |
| Average True Range (ATR) | 1.37 | 1.01 |
| MACD | 0.39 | 0.24 |
| Stochastic Oscillator | 92.17 | 82.27 |
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.